Neurizon Therapeutics Limited
About
0.06AUD-0.00 -1.59%
Closed • Updated at 01:39 GMT+00:00Market Cap$33.68M
Volume1.54M
Beta0.20
RSI32.38
Neurizon Therapeutics Limited — investor relations, events, news, and company updates on 6ix.
Latest News
May 27 2026
HEALEY ALS Platform Trial Regimen I expands to 240 participants
May 26 2026
HEALEY ALS Trial Regimen I Expands to 240 Participants
May 13 2026
Ethics Approval Received for NUZ-001 Oral Liquid P1 Study
Apr 16 2026
Placement of Entitlement Offer Shortfall
Apr 1 2026
NUZ-001 Data Shows Multi-Pathway Protein Clearance
Recent Videos
Neurizon Therapeutics' clinical progress and board strengthening underway
May 18, 2026
Neurizon Therapeutics' NUZ-001 is building momentum in ALS trial
Apr 07, 2026
Neurizon Therapeutics doses first patient in HEALY ALS platform trial
Feb 27, 2026
Neurizon: Potentially developing a treatment for motor neurone disease
Feb 26, 2026
Community Chat
Ask AI
Try asking